Awad Mohannad A, Hallgarth Luke, Barayan Ghassan A, Shahait Mohammed, Abu-Hijlih Ramiz, Farkouh Ala'a, Azhar Raed A, Alghamdi Musab M, Bugis Ahmad, Yaiesh Said, Aldousari Saad, Barham Alaeddin, Saed Mohamed, Moussa Ayman, Hassen Waleed, Naud Shelly, Plante Mark K, Grunert Richard
Department of Surgery, Division of Urology, University of Vermont Medical Center, Burlington, VT, USA.
Department of Surgery, King Abdulaziz University, Rabigh, Saudi Arabia.
Arab J Urol. 2021 Nov 28;20(2):88-93. doi: 10.1080/2090598X.2021.2002636. eCollection 2022.
Tocreate and validate a translated Arabic version of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP), a validated patient-reported outcome (PRO) widely used for assessing the quality of life in patients with prostate cancer (PCa).
Using the established protocol as defined by the Professional Society for the Health Economics and Outcomes Research (ISPOR) for translating patient care questionnaires, a harmonised translated Arabic version of EPIC-CP was created. The questionnaire was tested in native Arabic speakers from four different Arabic countries (Saudi Arabia, United Arab Emirates, Jordan, and Kuwait). Cronbach's alpha and interclass coefficient correlation (ICC) analyses were used to test the internal consistency and test-retest reliability, respectively. In addition, PCa characteristics were collected for participants.
In total, 168 patients with PCa participated in the study (39 from Saudi Arabia, 23 from United Arab Emirates, 65 from Jordan, and 41 from Kuwait). In all, 52 (31%) participants repeated the questionnaire for test-retest reliability analysis. The median (interquartile range [IQR]) age of patients included in the study was 66 (61-71) years. The median (IQR) PSA level was 9.8 (6-19) ng/mL. Most patients had Grade Group 2 PCa at diagnosis (31%), clinical stage cT1 (42%), managed primarily by urology (79%), and the primary treatment was radical prostatectomy (71%). The total Cronbach's alpha coefficient was 0.84 demonstrating an acceptable internal consistency. The total ICC was also acceptable at 0.64.
The Arabic version of the EPIC-CP is a reliable and valid tool for assessing health-related quality of life for Arabic patients with PCa.
创建并验证用于临床实践的前列腺癌扩展综合指数（EPIC-CP）的阿拉伯语翻译版本，EPIC-CP是一种经过验证的患者报告结局（PRO），广泛用于评估前列腺癌（PCa）患者的生活质量。
按照卫生经济与结果研究专业协会（ISPOR）定义的既定方案翻译患者护理问卷，创建了统一的EPIC-CP阿拉伯语翻译版本。该问卷在来自四个不同阿拉伯国家（沙特阿拉伯、阿拉伯联合酋长国、约旦和科威特）的阿拉伯语母语者中进行了测试。分别使用克朗巴哈系数（Cronbach's alpha）和组内相关系数（ICC）分析来测试内部一致性和重测信度。此外，收集了参与者的PCa特征。
共有168例PCa患者参与了该研究（39例来自沙特阿拉伯，23例来自阿拉伯联合酋长国，65例来自约旦，41例来自科威特）。共有52例（31%）参与者重复填写问卷以进行重测信度分析。纳入研究的患者中位年龄（四分位间距[IQR]）为66（61 - 71）岁。中位（IQR）前列腺特异性抗原（PSA）水平为9.8（6 - 19）ng/mL。大多数患者在诊断时为2级前列腺癌（31%），临床分期为cT1（42%），主要由泌尿外科管理（79%），主要治疗方式为根治性前列腺切除术（71%）。克朗巴哈系数总系数为0.84，表明内部一致性可接受。组内相关系数总系数为0.64，也可接受。
EPIC-CP阿拉伯语版本是评估阿拉伯语PCa患者健康相关生活质量的可靠且有效的工具。
